Oral Antibiotics Market, by Class, Application, Drug Origin, Spectrum Of Activity, Drug Type : Global Opportunity Analysis and Industry Forecast, 2020–2027

Oral Antibiotics Market, by Class, Application, Drug Origin, Spectrum Of Activity, Drug Type : Global Opportunity Analysis and Industry Forecast, 2020–2027

  • June 2020 •
  • 329 pages •
  • Report ID: 5939250 •
  • Format: PDF
Oral Antibiotics Market, by Class (Beta lactam & beta lactamase inhibitors, Quinolones, Macrolide, and Others), Application (Community-Acquired Respiratory Tract Infections (CARTIS), Urinary Tract Infections (UTIS), Dental, and Others), Drug Origin (Natural, Semisynthetic, Synthetic), Spectrum Of Activity (Broad-Spectrum Antibiotic, Mid/Narrow-Spectrum Antibiotic), Drug Type (Branded And Generics): Global Opportunity Analysis and Industry Forecast, 2020–2027

The global oral antibiotics market generated $18,365.80 million in 2018, and is projected to reach $23,306.10 million by 2027, growing at a CAGR of 2.7% from 2019 to 2027.

Antibiotic is an antimicrobial substance or a compound that fights against bacterial infections and sometimes with protozoan infections, but not viral infections. These are medications that either stop bacteria from growing or kill bacteria directly, referred as bacteriostatic and bactericidal antibiotics, respectively. There are several types of antibiotics easily available at drug stores and in hospitals with a prescription or without a prescription in most of countries. Antibiotics are mostly used during transplants, dialysis, suppressed immune system, and joint replacement.

There is an increase in demand for antibiotics, owing to increased consumption in low- and middle-income countries (LMICs) and rise in prevalence of infectious diseases. In addition, development of novel approaches for new antibiotics to treat bacterial infections and large number of clinical trials further drive the market growth. However, development of antibiotic resistance, driven by misuse of antibiotics and time taken for regulatory approvals are projected to impede the market growth. On the contrary, discovery of advanced prospect molecules and novel combination therapies to treat antibiotic-resistant microbial infections are expected to offer significant profitable opportunities for the market players.
The global oral antibiotics market is segmented on the basis of class, application drug origin, spectrum of activity, application, and region. On the basis of class, the market is classified into beta lactam & beta lactamase inhibitors, quinolones, macrolides, and others. Beta lactam & beta lactamase inhibitors is further segmented into Penicillin, Cephalosporin, and others. By application, the market is divided into community- respiratory tract infections (CARTIS), urinary acquired tract infections (UTIS), dental, and others. Depending on drug origin, it is categorized into natural, semisynthetic, and synthetic. According to the spectrum of activity, it is bifurcated into broad-spectrum antibiotic and narrow-spectrum antibiotic. By drug type, it is divided into branded and generics. Region wise, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.
Depending on class, the market is categorized into Beta lactam & beta lactamase inhibitors, Quinolones, Macrolide, and Others. The beta lactam & beta lactamase inhibitors segment was the highest contributor to the market in 2018. The segment is a major revenue contributor, owing to its broad-spectrum of activity A broad-spectrum antibiotic fights both Gram-negative and Gram-positive bacteria as well as effective on the multiple groups of bacterial infections.
On the basis of application, the oral antibiotics market is classified into community-acquired respiratory tract infections (CARTIs), urinary tract infections (UTIs), dental, and others. The CARTIs segment is further segmented into upper respiratory tract infections (URTI) and lower respiratory tract infections (LRTI). The dental segment is further divided into combination and monotherapies.
On the basis of drug origin, the oral antibiotics market is classified into natural, semisynthetic, and synthetic. The synthetic segment generated highest revenue in 2018, and is anticipated to maintain its dominance throughout the forecast period. This is attributed to the fact that semisynthetic oral antibiotics have improved coverage and effectiveness against a wide range of organisms.

KEY BENEFITS FOR STAKEHOLDERS
• The study provides an in-depth analysis of the global oral antibiotics market size along with the current trends and future estimations to elucidate the imminent investment pockets.
• It offers market analysis from 2020 to 2027, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
• A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities.
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global oral antibiotics market growth.

KEY MARKET SEGMENTS

By Class
• Beta Lactam and Beta Lactamase Inhibitors
o Penicillin
Broad Spectrum Penicillin
Mid/Narrow Spectrum Penicillin
o Cephalosporin
o Others
• Quinolone
• Macrolide
• Others

By Application
• Community-respiratory tract infections (CARTIS)
o Upper Respiratory Tract Infections (URTI)
o Lower Respiratory Tract Infections (LRTI)
• Urinary acquired tract infections (UTIS)
• Dental
o Combination
o Monotherapies
• Others

By Drug Origin
• Natural
• Semisynthetic
• Synthetic

By Spectrum of Activity
• Broad-spectrum Antibiotic
• Narrow-spectrum Antibiotic

By Drug Type
• Branded
• Generic

By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o France
o Spain
o Italy
o UK
o Russia
o Rest of Europe
• Asia-Pacific
o Japan
o India
o China
o Pakistan
o Vietnam
o Rest of Asia-Pacific
• LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Turkey
o Rest of LAMEA

List of key players profiled in the report
• Abbott Laboratories
• Allergan Plc.
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Merck & Co. Inc.
• Mylan N.V.
• Novartis International AG (Sandoz)
• Pfizer Inc.
• Sanofi
• Teva Pharmaceutical Industries Ltd.